CHAPTERS
Why the U.S. allows prescription drug ads (and what makes them misleading)
Joe and John open by contrasting the U.S. with New Zealand—two of the only countries that allow direct-to-consumer prescription advertising. Abramson explains why U.S. ad bans are difficult (First Amendment protections), but argues ads could be forced to disclose more meaningful, less manipulative facts.
Regulating ad truthfulness vs. banning ads: pragmatic constraints
Rogan argues that any ad creates room for manipulation, while Abramson takes a pragmatic stance that ads likely won't disappear. They discuss possible rules that would make ads longer, more standardized, and harder to spin, reducing their persuasive power.
Big Pharma’s job is profit: how incentives distort medical knowledge
Abramson and Rogan agree drugs can be life-saving, but warn that unchecked profit incentives encourage manipulation. Abramson frames the core problem as industry control over information flowing to doctors and patients in a uniquely unregulated U.S. system.
Hidden trial data and the Bextra case: why even DOJ outcomes can stay opaque
Abramson describes his role as an expert witness and the limitations confidentiality agreements impose, even after major government action. The discussion expands into the broader problem: companies own trial data, peer reviewers can’t access it, and the public often can’t see what was proven in enforcement actions.
Vioxx as a case study in fraud, harm at scale, and weak punishment
Abramson explains how the Vioxx story triggered his deeper investigation into pharma manipulation. He details how omitted cardiovascular events could flip statistics, how long the drug stayed on the market, and how penalties failed to deter future behavior.
From trusted clinician to skeptic: Abramson’s path through practice and litigation
Abramson recounts how he initially trusted the literature, then noticed commercialization shaping continuing medical education and journals. Litigation access to internal company records confirmed the scale and mechanics of manipulation.
Neurontin and off-label marketing: ‘rejiggering’ trial outcomes to sell efficacy
Abramson describes Kaiser’s lawsuit over Pfizer’s Neurontin marketing and explains a key statistical trick: presenting within-group improvement while ignoring the placebo comparison. They connect this tactic to broader confusion around interpreting treatment success without proper controls.
COVID therapeutics controversy: ivermectin, monoclonals, and what ‘not enough data’ means
Rogan and Abramson discuss the public fight over ivermectin and the media focus on one drug despite multi-treatment protocols. Abramson argues derision is out of bounds, explains why causality requires proper trials, and notes financial incentives shape what gets studied.
America’s poor health outcomes and massive overspending: the bigger scoreboard
Abramson zooms out to show how U.S. health outcomes lag wealthy peers despite far higher spending. He cites falling healthy life expectancy rank, excess mortality, and the staggering annual cost premium the U.S. pays for inferior results.
Repair agenda: coalitions, cost-effectiveness, and treating lifestyle as the main lever (80%)
Abramson argues the fix requires informed, politically active constituencies—patients, doctors, and employers—who recognize they’re being harmed by distorted incentives. He emphasizes that most health is driven by life circumstances and behavior, and warns against reforms that only shift payment without reducing underlying costs.
Insulin, Inc.: how insulin analogs replaced cheaper options without clear benefit
Abramson explains how insulin moved from animal sources to recombinant human insulin, then to expensive analogs marketed as ‘more physiologic.’ He argues standards and incentives were manipulated to entrench tighter control targets, driving widespread use of far costlier insulin despite limited evidence of superior outcomes for many patients.
Vaccine safety tradeoffs: myocarditis data, VAERS limits, and uncertainty over long-term risk
Prompted by Rogan’s concerns, Abramson reviews CDC and Israeli myocarditis estimates and the challenges of passive reporting systems. They debate risk/benefit framing for children, the role of comorbidities, and why mandates intensify suspicion when long-term outcomes remain unknown.
Aduhelm and FDA credibility: accelerated approvals, pricing shocks, and ‘nexus of influence’
Abramson presents Aduhelm as a modern example of approval despite limited clinical benefit and substantial side effects, paired with extreme pricing. He ties this to broader ‘market failure’: journals, academic centers, and professional societies financially intertwined with industry, requiring structural reforms like data transparency and independence from pharma money.
